Can Measurements of IGF-1 and IGFBP-3 Improve the Sensitivity of Prostate-Cancer Screening?

Lancet. 2000 Dec 2;356(9245):1902-3. doi: 10.1016/S0140-6736(00)03266-9.

Abstract

Further well designed studies are urgently needed to clarify if use of prostate-specific antigen (PSA) as a diagnostic test for prostate cancer can be improved by incorporating measurements of serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding-protein 3 (IGFBP-3), and if these measurements might also identify men at higher risk.

Publication types

  • Letter

MeSH terms

  • Humans
  • Insulin-Like Growth Factor Binding Protein 3 / blood*
  • Insulin-Like Growth Factor I / metabolism*
  • Male
  • Mass Screening
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / diagnosis*
  • Sensitivity and Specificity

Substances

  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor I
  • Prostate-Specific Antigen